


Investigator Site File (ISF) Contents List for studies not involving Investigational Medicinal Products (non-CTIMP) – Guidance Page

This contents list should be used by participating (research) sites in a CTIMP to create an ISF.

Please use the decision tree below to check which contents list(s) is/are required for your study



Tips for using this contents list:

1. Not all documents/sections listed below will be applicable to all studies.
Where an entire section is **not applicable**, it should be marked as such, but the original numbering of the section should be retained, this ensures a consistent filing system across all University of Leicester sponsored studies.
2. If a listed document is stored elsewhere, a note to file should be included to record its location and confirm how access can be gained. Where a document is stored electronically, please include the file path.
3. Documents should be filed in reverse chronological order (newest on top) with superseded documents marked as such.
4. To supersede a document you should;
 - Strike a single line through the front page of the document
 - Write superseded by and add the version and date of the updated document i.e. Superseded by v2.3 01/01/2023
 - Initial or sign and date next to the annotation (please note that anybody undertaking TMF maintenance should be delegated this task on the Delegation of Authority and Signature Log)
5. A copy of the relevant contents list should be placed at the front of each TMF/ISF folder. The guidance pages do not require filing.

Investigator Site File (ISF) Contents List for studies not involving Investigational Medicinal Products (non-CTIMP)

Study Title:	
Site number/name:	
Principal Investigator:	

Section 1: Study Management	
1.1	List of relevant site contacts <i>e.g. research team members, laboratory departments, R&D/I departments etc</i>
1.2	List of relevant central study contacts <i>e.g. Study Management team, CTU, CI, Sponsor</i>
1.3	Study Documentation version control log/tracker (S-1015 Appendix 3)
Section 2: Protocol and Associated Documents	
2.1	Current Protocol <i>signed and dated by the Principal Investigator</i>
2.2	Superseded Protocol <i>signed and dated by the Principal Investigator</i>
2.3	Data Flow Diagram <i>(if separate to protocol)</i>
2.4	Template Protocol Deviation Log (S-1013 Appendix 2)
2.5	Current site Protocol Deviation Log
2.6	CAPA/Serious Breach <i>notifications and correspondence (if applicable)</i>
2.7	Template File Note (S-1013 Appendix 3)
2.8	Site File Note log <i>(if applicable)</i> (S-1013 Appendix 4)
Section 3: Study Documentation	
3.1	Current, site localised study documents <i>e.g. Participant Information Sheets, Template Informed Consent Forms, Letters, Posters, Questionnaires etc</i>
3.2	Superseded, site localised study documents <i>e.g. Participant Information Sheets, Template Informed Consent Forms, Letters, Posters, Questionnaires etc (where applicable)</i>
Section 4: Initial Site Approvals	
4.1	Site Sponsor Green Light
4.2	Site R & D/I approval <i>(Confirmation of Capacity and Capability)</i>
4.3	Site Feasibility Assessment
4.4	Relevant correspondence
Section 5: Amendments	
5.1	Substantial Amendments (repeat per substantial amendment) <ul style="list-style-type: none"> • Site Sponsor Green Light for the implementation of the amendment • Site R&D/I amendment approval <i>(Confirmation of Capacity and Capability) (if applicable)</i> • Evidence of site research team and R&D/I notification of amendment • Copy of the completed amendment tool • Relevant correspondence
5.2	Non substantial Amendments (repeat per non-substantial amendment) <ul style="list-style-type: none"> • Site Sponsor Green Light/Approval for the implementation of the amendment • Site R&D/I amendment approval <i>(Confirmation of Capacity and Capability) (if applicable)</i> • Evidence of site research team R&D/I notification of amendment (ideally stating 35-day implementation date) • Copy of the completed amendment tool • Relevant correspondence
Section 6: Investigator Site Personnel	
6.1	Template Delegation of Authority and Signature Log (DoA) (S-1010 Appendix 2)
6.2	Site Delegation of Authority and Signature Log (DoA)
6.3	Site personnel documents <i>(covering the duration of involvement with the study)</i> <i>The following documents should be filed as relevant per person listed on the DoA;</i> <ul style="list-style-type: none"> • Signed and dated research CV <i>(HRA template recommended)</i> • Evidence of GCP training • Evidence of consent training <i>(if applicable)</i>

	<ul style="list-style-type: none"> • Evidence of study specific training e.g. Logs showing protocol training (S-1020 Appendix 1) • Sponsor SOP read logs (S-1011 Appendix 3) • Study Specific SOP read logs (if applicable)
6.4	Investigator tracking log (A spreadsheet should be maintained which lists all the individuals involved in the study at the site and the dates of relevant training/documents (S-1015 Appendix 13))
Section 7: Participant Documentation	
7.1	Template Screening Log (S-1011 Appendix 5)
7.2	Site Screening Log(s) (containing non-identifiable participant data only)
7.3	Template Participant Enrolment Log (S-1011 Appendix 6)
7.4	Site Participant Enrolment log (not to be removed from site)
Section 8: Informed Consent	
8.1	Original Completed Consent Forms
Section 9: Standard Operating Procedures (SOPs)	
9.1	Note to file signposting the location of the most current Sponsor SOPs. e.g. web address/electronic quality management system
9.2	Current study specific SOPs or note to file signposting the location (if applicable)
9.3	Superseded study specific SOPs (if applicable)
Section 10: Statistics and Analysis	
10.1	Procedure for randomisation/code break (if applicable)
10.2	Master Randomisation List or location e.g. in Sealed Envelope (if applicable)
10.3	Evidence of randomisation i.e. envelopes/email/IVRS (unblinded study only)
Section 11: Data Management	
11.1	Current CRF Templates
11.2	Superseded CRF Templates (if applicable)
11.3	File note (or equivalent) providing details of electronic/paper case report form storage/security
11.4	Any other data management documents e.g. data management queries/privacy notices
Section 12: Safety Reporting	
12.1	Template Serious Adverse Event (SAE) reporting form (S-1009 Supporting document 1)
12.2	Superseded template Serious Adverse Event (SAE) reporting form(s) (if applicable)
12.3	Site SAE/SAR/SUSAR Tracking Log (S-1009 Appendix 5)
12.4	Site SAE/SAR/SUSAR reports and associated acknowledgement correspondence
12.5	Evidence of site SUSAR notification (if applicable)
Section 13: Clinical Laboratory (if applicable)	
13.1	Lab Manual/sample processing manual
13.2	List of all laboratories used
13.3	Site laboratories Certificates of Accreditation
13.4	Site laboratories Normal Reference Ranges (including revisions)
13.5	Details of site sample storage facilities/processes
13.6	Site Sample Shipment Receipt(s)/Tracking Log(s) (if applicable)
13.7	Site Temperature Logs for sample storage
13.8	Site sample storage instructions
13.9	Site inventory/destruction log of all samples/specimens
13.10	Details of local sample storage arrangements for all samples held for future research
Section 14: Monitoring	
14.1	Template Monitoring Visit Log
14.2	Current site Monitoring Visit Log (if applicable)
14.3	Signed site Source Data Agreement (S-1007 Appendix 4)
14.4	Site Initiation Visit (SIV) documentation e.g. agenda, signed closed SIV report and outstanding actions list, signed SIV log and relevant correspondence (if applicable)
14.5	Site Monitoring documentation e.g. signed closed monitoring visit report(s)/CAPAs and relevant correspondence (if applicable)
14.6	Site External Audit documentation e.g. signed closed monitoring visit report(s)/CAPAs and relevant correspondence (if applicable)

14.7	Site data query management documentation <i>e.g. copies of internal audits/quality control checks</i>
14.8	Site Close out Visit (CoV) documentation <i>e.g. signed closed COV report and outstanding actions list and relevant correspondence</i>
Section 15: Financial/Legal	
15.1	Site Contracts/Contract Addendums (and any relevant correspondence/documents) <i>(where applicable)</i>
15.2	Study Specific Indemnity <i>(including updates if applicable)</i>
15.3	Sponsor Insurance Certificates <i>covering the duration of the study</i>
15.4	Site signed agreements <i>e.g. OID/mNCA (including any updates)</i>
15.5	Schedule of Events (SoE)/Validated SoECAT <i>(including any updates)</i>
15.6	Site to Participant Identification Centre (PIC) documents <i>(if applicable)</i> <ul style="list-style-type: none"> • PIC site tracker (S-1015 Appendix 12) Site to PIC site documents <i>(repeat per PIC site)</i> <ul style="list-style-type: none"> • Site to PIC site(s) Sponsor Green Light • PIC site <i>Confirmation of Capacity and Capability (if applicable)</i> • Signed agreement(s) <i>e.g. site to PIC mNCA</i> • Relevant Correspondence
15.7	Misc. financial documents/correspondence
Section 16: Meetings	
16.1	Site/Investigator meetings documentation <i>e.g Meeting agendas, reports, minutes and correspondence</i>
Section 17: End of Study Reporting	
17.1	Signed End of Study Declaration Form
17.2	Evidence of notification of End of Study to Local R & D/I department
Section 18: Correspondence	
18.1	Important correspondence with CI/Sponsor and internal site correspondence
18.2	Newsletters <i>(where applicable)</i>
18.3	Any other study specific correspondence <i>(where applicable)</i>
Section 19: Miscellaneous	
19.1	